NEW YORK — Bionano Genomics said on Thursday that it has priced an $18 million public offering of stock and warrants.
The company also recently announced its participation in a project investigating the genetics of susceptibility to COVID-19.
Through the offering, the San Diego-based company will sell 54.5 million shares of its common stock — or prefunded warrants to purchase common stock in lieu thereof — along with warrants to purchase an additional 54.5 million common shares. Each share will be sold with one warrant for $.33.